About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Pfizer Investigator Stalked Neurontin Witness; Who Paid Off the Plaintiffs?

By Jim Edwards | Jul 30, 2009

The first of Pfizer’s Neurontin mass tort cases could not have been stranger: The plaintiffs dropped the case after a mystery donor paid them $50,000; a Pfizer investigator was accused by a witness of blocking his driveway and scaring his family; and CEO Jeff Kindler made it personal between him and the lead plaintiffs’ lawyer, Mark Lanier.

Lanier said the donation came from another plaintiffs’ attorney who had been watching the case in the courtroom. He told the AP:

“Isn’t that wild?” Lanier said. “I’ve never had anything like that happen before.”

Wild, and also convenient. As BNET noted July 24, the case was described as “very tough” by the judge. The plaintiff’s family claimed Neurontin was prescribed off-label for their daughter, Susan Bulger, who killed herself. The anti-seizure drug was not indicated for depression. But the dead woman had attempted suicide before and had a history of mental problems. The case was probably a loser for Lanier. The real mystery is why he decided to bring it in the first place.

Pfizer can breathe a sigh of relief, too. The first witness, former Pfizer drug sales rep David Franklin, told the court he was stalked by a Pfizer pflunky. AmLaw:

He told the courtroom that the day before trial, a private investigator hired by Pfizer came to his house, blocked the driveway, and would not leave until his wife called the police. After Franklin’s testimony — during which he said that the private investigator had yelled at his wife and frightened his young daughter — Judge Saris told [Pfizer lawyer William Ohlemeyer of Boies, Schiller & Flexner] that “no one should be going after Dr. David Franklin anymore.”

Ohlmeyer confirmed the incident to the AP:

“It sounds like this didn’t happen the way it should have happened,” Ohlemeyer said. “We apologized to (Franklin) for what happened.”

Having performed The Great Escape — the settlement truncates any more entertaining testimony about what else Pfizer’s spies might have gotten up to in the case –  Kindler then decided to open his mouth. Bloomberg:

“We are pleased to have been vindicated in this case,” Jeffrey Kindler, chief executive officer of New York-based Pfizer, said in a phone interview on Bloomberg Television today. Neurontin has been “prescribed to treat millions of patients safely and effectively for many, many years and it’s been widely studied for more than two decades,” he said.

“Vindicated?” Lanier didn’t like that:

Kindler’s comments are “outrageous,” Lanier said. “All Pfizer got today was a six-month stay of execution. We have 1,200 more of these cases to go.”

In a media battle, the freewheeling Lanier will beat Kindler every day of the week. The company had made a great case that Neurontin was the least of Bulger’s problems. The plaintiff was so unsympathetic that the judge even had to warn the jury that she was not related to Boston gangster Whitey Bulger. Kindler should stick to winning these things on the facts. The “vindication” here only sets the company up for more difficult cases to come.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Pfizer told to avoid Neurontin witness

    Fierce Pharma - 104 days 20 hours 45 minutes ago

    Since the surprise settlement of Pfizer's first Neurontin-related case to hit trial, the company and its lawyers have been ordered to stay away from a key plaintiffs' witness. Dr. David Franklin, who brought a whistleblower suit against the company (Warner-Lambert at the time), told the court that he and his family had been scared out of their...

  • Neurontin case dropped after mystery donation

    Fierce Pharma - 116 days 22 hours 20 minutes ago

    Mystery donor to the rescue. The first Neurontin trial is kaput, thanks to some secret moneybags who set up a trust for the daughter of suicide victim Susan Bulger. The Bulger family's attorney, Mark Lanier, dropped their suit yesterday after said donor stepped up. "It was the best thing for the family," a family spokesman told Bloomberg. The...

  • Pharma Giles writes - The mystery of the "mystery benefactor"

    PharmaGossip - 113 days 21 hours 2 minutes ago

    The first of Phoni ’s Yeuramorontin (grabacashin) mass tort cases collapsed today after the plaintiffs dropped the case following a mystery donation of $50,000. The lead plaintiffs’ lawyer, Mark Zanier, s aid that a mystery benefactor known only as a “Mr. J. B . Sinister (no relation)”, who had been watching the case in the...

  • Pfizer Accused of "Blatant Hypocrisy" Over Alleged Witness Tampering in Neurontin Case

    BNET Pharma - 54 days 18 hours 13 minutes ago

    Plaintiffs in the Neurontin litigation have accused Pfizer of "blatant hypocrisy" for insisting that witnesses should not contact each other in the

  • Pfizer - Neurontin: Lanier vs Kindler

    PharmaGossip - 117 days 5 hours 29 minutes ago

    Pfizer Inc. won’t face a verdict over claims its epilepsy drug Neurontin helped lead a Massachusetts woman to commit suicide, after her family dropped its lawsuit in the midst of trial. Susan Bulger’s family agreed to dismiss the suit after an anonymous donor offered to put money in a trust for her 10-year- old daughter, Regina, said Mark...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement